Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Pancreatic Neoplasms 1Neoplasms 1Adenocarcinoma 1

Interventions

Docetaxel 5Pemetrexed 4Capecitabine 4pembrolizumab 3Oxaliplatin 3icotinib 2Radiation 2Paclitaxel 2Gemcitabine 2Gefitinib 2Fluorouracil 2Drug Therapy 2Chemoradiotherapy 2Carboplatin 2sintilimab 1rucaparib 1regorafenib 1olaparib 1lenvatinib 1iron isomaltoside 1000 1ipatasertib 1iopromide 1gluconic acid 1elemene 1capecitabine-irinotecan combination 1aumolertinib 1atezolizumab 1anlotinib 1aflutinib 1XELOX 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Adenocarcinoma × PEGPH20 × Clear all
NCT03634332 2019-05-07

Second-line Study of PEGPH20 and Pembro for HA High Metastatic PDAC

Pancreatic Cancer Research Team

Phase 2 Unknown
35 enrolled
Gastrointestinal

Adenocarcinoma, Neoplasms, Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡